Research programme: cyclin dependent kinase 5 inhibitors - 4M Therapeutics
Alternative Names: 4MT-04; 4MT-04 seriesLatest Information Update: 15 Oct 2024
At a glance
- Originator 4M Therapeutics
- Class Neuroprotectants; Peptides
- Mechanism of Action Cyclin-dependent kinase 5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurodegenerative disorders
Most Recent Events
- 25 Sep 2024 Preclinical trials in Neurodegenerative disorders in USA (unspecified route) (4M Therapeutics pipeline, September 2024)